LifeMD vs MEDVi (2026): prices, structure, verdict

On tirzepatide, MEDVi↗ is cheaper: $399 versus $597 a month all-in — a $198 monthly gap, $2,376 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, MEDVi is cheaper: $299 versus $348 a month all-in — a $49 monthly gap, $588 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

LifeMD: the record, condensed

On tirzepatide, the number that matters at LifeMD is $597 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The all-in figure already contains a compulsory $149 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $448 would be exactly that kind of mirage.

To place the number: #17 of 17 verified programs, with the floor $382/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $7,164 monthly-billed.

LifeMD’s semaglutide program bills $348 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at LifeMD is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The all-in figure already contains a compulsory $149 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $199 would be exactly that kind of mirage.

Context for that figure: it ranks #20 of 20 in the verified semaglutide index — $215/month above the floor (Oak Longevity, $133) — and sits $1 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $4,176.

Operationally at LifeMD: shipping included; commitment program fee recurs monthly; cancellation program fee recurs until cancelled; pharmacy not publicly named — ask in writing before paying; states: 50 states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the LifeMD page · visit LifeMD ↗

MEDVi: the record, condensed

MEDVi’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

On semaglutide, the number that matters at MEDVi is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: MEDVi at $399, LifeMD at $597 — a $198 monthly spread that compounds to $2,376 over a maintenance year and $4,752 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $198 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; MEDVi has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $299 (MEDVi) against $348 (LifeMD). $49 a month sounds survivable; $588 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $49 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; MEDVi has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

A way to feel the $198 monthly gap: over a year it funds 6.0 extra months at MEDVi’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $4,752, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: LifeMD $597/mo month-to-month against MEDVi $399/mo month-to-month. The order holds: MEDVi leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: LifeMD $1,791 monthly; MEDVi $1,197 monthly — best path favors MEDVi by $594. 6 months: LifeMD $3,582 monthly; MEDVi $2,394 monthly — best path favors MEDVi by $1,188. 12 months: LifeMD $7,164 monthly; MEDVi $4,788 monthly — best path favors MEDVi by $2,376. 24 months: LifeMD $14,328 monthly; MEDVi $9,576 monthly — best path favors MEDVi by $4,752.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: LifeMD $1,044 vs MEDVi $897 — $147 to MEDVi. 6 mo: LifeMD $2,088 vs MEDVi $1,794 — $294 to MEDVi. 12 mo: LifeMD $4,176 vs MEDVi $3,588 — $588 to MEDVi. 24 mo: LifeMD $8,352 vs MEDVi $7,176 — $1,176 to MEDVi.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: LifeMD publishes “50 states”; MEDVi publishes “priced differently in CA/NC on some plans” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: LifeMD — program fee recurs monthly; program fee recurs until cancelled. MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

Insurance: only LifeMD does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: LifeMD third-party reported (captured 2026-08-05); MEDVi source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #17 and #14 of 17: between them lie 2 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #20 and #18 of 20: between them lie 1 other program, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between LifeMD and MEDVi

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (LifeMD: program fee recurs until cancelled; MEDVi: 12-month plan applies to lowest rate) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings